Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding

Thrombosis and Haemostasis

Volumn 89, Issue 5, 2003, Pages 795-802

  Lewis, Deborah A ^a   Pound, Mary L ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ESH4; Factor VIII; Inhibitor; Phopsholipid binding; Von Willebrand factor

Indexed keywords

ALANINE; ASPARAGINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8C2; METHIONINE; MUTANT PROTEIN; PHENYLALANINE; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; LIPOSOME; PHOSPHATIDYLSERINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOPRECIPITATION; INHIBITION KINETICS; MEMBRANE BINDING; MUTAGENESIS; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; IMMUNOLOGY; METABOLISM; MISSENSE MUTATION; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; BINDING SITES; EPITOPE MAPPING; FACTOR VIII; HUMANS; LIPOSOMES; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PHOSPHATIDYLSERINES; PHOSPHOLIPIDS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; VON WILLEBRAND FACTOR;

EID: 0037846480     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613464     Document Type: Article

References (24)

1. Sadler JE, Davie EW. Hemophilia A, Hemophilia B and von Willebrand's disease. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The Molecular Basis of Blood Diseases. 3 Ed. Philadelphia: W. B. Saunders, 2001: 680-718.
2. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
3. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
4. Fay PJ, Coumans J-V, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-7.
5. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456-65.
6. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
7. Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
8. Jacquemin M, Pratt K, Spiegel C, Stoddard B, Desqueper B, Lavend'homme R, Benhida A, Gilles JG, Peerlinck K, Vermylen K, D'Oiron R, Saint-Remy J-M, Lavergne J-M. Deletion of residue Ala2201 in the factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by factor VIII inhibitor antibodies. Thromb Haemost 2001; Supplement: OC194 (Abstract).
9. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy J-M, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97: 169-74.
10. Gilbert GE, Kaufman RJ, Arena AA, Miao HZ, Pipe SW. Four hydrophobic amino acids of the factor VIIIC2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-81.
11. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007-14.
12. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
13. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospolipid. J Clin Invest 1989; 83: 1978-84.
14. Nordfang O, Ezban M, Dinesen B. Reactivity of factor VIII inhibitors in a micro ELISA for factor VIII: CAg and in solid phase immunoisolation of VIII: CAg. Thromb Haemost 1985; 53: 346-50.
15. Lewis DA, Moore KD, Ortel TL. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. Blood Coagul Fibrinolysis 2003; (In press).
16. Ortel TL, Moore KD, Ezban M, Kane WH. Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII. Thromb Haemost 1996; 75: 36-44.
17. Lewis DA, Moore KD, Ortel TL. Factor VIII Arg2304→His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex. Thromb Haemost 2001; 85: 260-4.
18. Ortel TL, Quinn-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 1994; 269: 15898-905.
19. Kane WH, Devore-Carter D, Ortel TL. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 1990; 29: 6762-8.
20. Kim SW, Ortel TL, Quinn-Allen MA, Yoo L, Worfolk L, Zhai X, Lentz BR, Kane WH. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38: 11448-54.
21. Gomori G. A modification of the colorimetric phosphorus determination for use with the photoelectric colorimeter. J Lab Clin Med 1942; 27: 955-60.
22. Kim SW, Quinn-Allen MA, Camp JT, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH. Identification of functionally important amino acid residues within the C2 domain of human factor V using alanine scanning mutagenesis. Biochemistry 2000; 39: 1951-8.
23. Vlot AJ, Koppelman SJ, Meijers JC, Dama C, Van Den Berg HM, Bouma BN, Sixma JJ, Willems GM. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
24. Izumi T, Kim SW, Greist A, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH, Ortel TL. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants: Identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost 2001; 85: 1048-54.